- 专利标题: COMPOUNDS FOR PROTEASOME ENZYME INHIBITION
-
申请号: US17169990申请日: 2021-02-08
-
公开(公告)号: US20210179663A1公开(公告)日: 2021-06-17
- 发明人: Mark S. Smyth , Guy J. Laidig
- 申请人: Onyx Therapeutics, Inc.
- 申请人地址: US CA Thousand Oaks
- 专利权人: Onyx Therapeutics, Inc.
- 当前专利权人: Onyx Therapeutics, Inc.
- 当前专利权人地址: US CA Thousand Oaks
- 主分类号: C07K5/107
- IPC分类号: C07K5/107 ; C07K5/087 ; C07K5/103 ; C07K5/08 ; A61K38/07 ; C07K5/117
摘要:
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
信息查询